Molecular mechanisms and adjuvant therapeutic potential of α-mangostin in cervical cancer.

Authors

Zheng Liu, Weilong Liu, Zhiqiang Liu

Published in

Discover oncology. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

Cervical cancer remains a significant global health challenge for women. Conventional treatments, including surgery, radiotherapy, and chemotherapy, are frequently limited by side effects and the development of drug resistance.
This review synthesizes the therapeutic potential of α-mangostin in cervical cancer, with particular emphasis on its anticancer properties and underlying molecular mechanisms.
We searched Google Scholar, PubMed, Scopus, Web of Science Core Collection, and ScienceDirect for preclinical and clinical studies on α-mangostin in cervical cancer, and the retrieved evidence was critically evaluated and summarized narratively.
α-Mangostin exhibits multiple anticancer effects in cervical cancer. It induces apoptosis, suppresses proliferation, modulates key signaling pathways, downregulates the human papillomavirus (HPV) oncogenes E6 and E7, and reverses chemoresistance.
Although these findings position α-mangostin as a promising adjuvant candidate for cervical cancer, the evidence remains preclinical. Dedicated clinical trials are needed before any therapeutic claim can be made, but continued investigation may ultimately help improve treatment outcomes and address the rising mortality associated with this disease.

PMID:
42469536
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.